Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × daratumumab × Plasma cell × Clear all

Phase

Status

Sponsor Class

OTHER 104 INDUSTRY 78 NETWORK 15 NIH 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Cyclophosphamide 4 Dexamethasone 3 pegylated granulocyte colony-stimulating factor 2 pegfilgrastim 2 fludarabine 2 carfilzomib 2 Etoposide 2 Cytarabine 2 Bortezomib 2 pomalidomide 1 fludarabine phosphate 1 daratumumab 1 Zoledronic Acid 1 Vaccination 1 Thiotepa 1 Renal Replacement Therapy 1 Prednisone 1 Pneumococcal Vaccines 1 Melphalan 1 Lenalidomide 1 Granulocyte Colony-Stimulating Factor 1 Cyclosporine 1 Atorvastatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡